Global Budesonide Market Growth 2023-2029

Global Budesonide Market Growth 2023-2029

Budesonide (BUD), sold under the brand name Pulmicort among others, is a steroid medication. It is available as an inhaler, pill, and Injectable Suspension. The inhaled form is used in the long term management of asthma and chronic obstructive pulmonary disease (COPD). The Injectable Suspension is used for allergic rhinitis and nasal polyps. The pills in a delayed release form may be used for inflammatory bowel disease including Crohn's disease, ulcerative colitis and microscopic colitis. Statistic for budesonide in this report includes three product types: Injectable Suspension, inhaler and Inhalation Powder.

LPI (LP Information)' newest research report, the “Budesonide Industry Forecast” looks at past sales and reviews total world Budesonide sales in 2022, providing a comprehensive analysis by region and market sector of projected Budesonide sales for 2023 through 2029. With Budesonide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Budesonide industry.

This Insight Report provides a comprehensive analysis of the global Budesonide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Budesonide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Budesonide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Budesonide and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Budesonide.

The global Budesonide market size is projected to grow from US$ 8024.6 million in 2022 to US$ 10090 million in 2029; it is expected to grow at a CAGR of 10090 from 2023 to 2029.

North America is the largest market with about 36% revenue market share. Followed by Asia-Pacific and Europe, accounting for about 60% revenue market share.

The key players are AstraZeneca, Teva, Mylan, Sandoz, Cosmo Pharmaceuticals, Salix, Chiesi Farmaceutici, Orion Corporation, Cipla, Synmosa Biopharma, Lunan Better Pharma, Shanghai Sine Promod etc. AstraZeneca is the largest manufacturer with about 56% revenue market share.

This report presents a comprehensive overview, market shares, and growth opportunities of Budesonide market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
Injectable Suspension
Aerosols
Inhalation Powder
Tablet and Capsule

Segmentation by application
Respiratory Disease Treatment
Nose Disease Treatment
Inflammatory Bowel Disease Treatment
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Teva
Mylan
Sandoz
Cosmo Pharmaceuticals
Salix
Chiesi Farmaceutici
Orion Corporation
Cipla
Synmosa Biopharma
Lunan Better Pharma
Shanghai Sine Promod

Key Questions Addressed in this Report

What is the 10-year outlook for the global Budesonide market?

What factors are driving Budesonide market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Budesonide market opportunities vary by end market size?

How does Budesonide break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.